陳 瓏方

Medicine & Life Sciences

1. 2,5-dibromo-2-(beta-naphthyl)indan-1,3-dione 9%
2. Action Potentials 10%
3. Anti-Citrullinated Protein Antibodies 80%
4. Antibodies 9%
5. Arthritis 50%
6. Autoantibodies 10%
7. Autoimmune Diseases 50%
8. Biological Factors 10%
9. C-Reactive Protein 51%
10. Colchicine 10%
11. Comorbidity 15%
12. Confidence Intervals 21%
13. Cyclophosphamide 13%
14. Cyclosporine 9%
15. Databases 9%
16. Dermatomyositis 23%
17. Edema 15%
18. Gout 69%
19. Gouty Arthritis 86%
20. Health Care Costs 52%
21. Hepacivirus 53%
22. Hepatitis B virus 56%
23. Hepatocellular Carcinoma 46%
24. Histamine Antagonists 67%
25. Hot Temperature 8%
26. Immunosuppressive Agents 8%
27. Interstitial Lung Diseases 10%
28. Methotrexate 9%
29. National Health Programs 11%
30. Nerve Fibers 11%
31. Non-Steroidal Anti-Inflammatory Agents 9%
32. Odds Ratio 16%
33. Osteomyelitis 62%
34. Periosteum 12%
35. Pneumocystis Pneumonia 72%
36. Population 22%
37. Proportional Hazards Models 8%
38. Rheumatic Diseases 61%
39. Rheumatoid Arthritis 100%
40. Rheumatologists 11%
41. Sjogren's Syndrome 10%
42. Steroids 14%
43. Subcutaneous Tissue 21%
44. Synovial Membrane 11%
45. Synovitis 68%
46. Systemic Lupus Erythematosus 9%
47. Systemic Scleroderma 11%
48. Taiwan 10%
49. tocilizumab 9%
50. Virus Diseases 49%